Pages that link to "Q66753681"
Jump to navigation
Jump to search
The following pages link to Josef S Smolen (Q66753681):
Displaying 50 items.
- Interleukin-6: a new therapeutic target (Q21195659) (← links)
- The role of osteoprotegerin in arthritis (Q24797889) (← links)
- JNK1 is not essential for TNF-mediated joint disease (Q24799357) (← links)
- SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus (Q24804939) (← links)
- Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo (Q24812465) (← links)
- The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function (Q24816880) (← links)
- Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score (Q24817087) (← links)
- Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease (Q26753120) (← links)
- The changing landscape of biosimilars in rheumatology (Q26766515) (← links)
- EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide (Q26778262) (← links)
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update (Q26859134) (← links)
- Development of patient-centred standards of care for osteoarthritis in Europe: the eumusc.net-project (Q26998214) (← links)
- The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016 (Q27007783) (← links)
- Relevant concepts of functioning for patients with systemic lupus erythematosus identified in a Delphi exercise of experts and a literature review (Q27014980) (← links)
- Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement (Q27021115) (← links)
- EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria (Q27026582) (← links)
- A dynamic real time in vivo and static ex vivo analysis of granulomonocytic cell migration in the collagen-induced arthritis model (Q27304648) (← links)
- Does mixed connective tissue disease exist? Yes (Q28266118) (← links)
- Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: Involvement of impaired integrin activation and immunologic synapse formation (Q29027508) (← links)
- Rheumatoid arthritis. (Q30244019) (← links)
- How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion (Q30688001) (← links)
- Contributions of ultrasound beyond clinical data in assessing inflammatory disease activity in rheumatoid arthritis: current insights and future prospects (Q30822825) (← links)
- Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis (Q30986148) (← links)
- Endothelial precursor cells in the synovial tissue of patients with rheumatoid arthritis and osteoarthritis (Q31091902) (← links)
- Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis (Q31107452) (← links)
- Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation (Q32175831) (← links)
- Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: new aspects after the fall of the pyramid and the rise of new therapeutics (Q33194874) (← links)
- Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states (Q33222832) (← links)
- The definition and measurement of disease modification in inflammatory rheumatic diseases (Q33234955) (← links)
- Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components (Q33256077) (← links)
- The health assessment questionnaire in routine clinical practice (Q33276525) (← links)
- Is computer-assisted management necessary for patients with early rheumatoid arthritis? (Q33336356) (← links)
- The importance of reporting disease activity states in rheumatoid arthritis clinical trials (Q33365105) (← links)
- The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical care (Q33517263) (← links)
- Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review (Q33535269) (← links)
- Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial (Q33731705) (← links)
- CD4⁺CD25⁻Foxp3⁺ T cells: a marker for lupus nephritis? (Q33765809) (← links)
- Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction (Q33820509) (← links)
- Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature (Q33859169) (← links)
- Gait changes precede overt arthritis and strongly correlate with symptoms and histopathological events in pristane-induced arthritis (Q33923285) (← links)
- Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression (Q33976269) (← links)
- Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints (Q34033218) (← links)
- Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy (Q34092469) (← links)
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs (Q34110066) (← links)
- Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis (Q34113970) (← links)
- 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative (Q34130671) (← links)
- Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index (Q34210394) (← links)
- Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study (Q34237578) (← links)
- Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity (Q34338308) (← links)
- Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients (Q34390395) (← links)